MARKET

PSTV

PSTV

Plus Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.400
-0.310
-11.44%
After Hours: 2.500 +0.1 +4.17% 17:18 03/03 EST
OPEN
2.615
PREV CLOSE
2.710
HIGH
2.700
LOW
2.400
VOLUME
335.79K
TURNOVER
--
52 WEEK HIGH
5.42
52 WEEK LOW
0.9310
MARKET CAP
22.00M
P/E (TTM)
-1.3375
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Plus Therapeutics to Participate in Upcoming Virtual Conferences
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of ...
GlobeNewswire · 9h ago
Nextech Successfully Launches its Ad Network Featuring Augmented Reality Capabilities on its Virtual Events Properties, Delivering Millions of Impressions
Nextech AR Solutions ("Nextech'' or the "Company") (OTCQB: NEXCF) (NEO: NTAR.NE) (CSE: NTAR) (FSE: N29), a diversified leading provider of virtual and augmented reality (AR) experience technologies and services for eCommerce, education, advertising, confer...
Business Wire · 1d ago
Emerging Growth Conference 2 Announced for March 3, 2021 Niche Companies in Technology, AR, eCommerce, Beverage and more in Attendance
GlobeNewswire · 2d ago
Nextech AR Solutions to Present at the Emerging Growth Conference on March 3, 2021
Business Wire · 2d ago
BRIEF-Plus Therapeutics Files Prospectus Relates To Offer And Sale Of Up To 4.5 Mln Shares Of Co's Common Stock
reuters.com · 5d ago
Thinking about buying stock in Powerbridge Technologies, BioCryst Pharma, Oramed Pharma, Ampio Pharma, or Plus Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PBTS, BCRX, ORMP, AMPE, and PSTV.
PR Newswire - PRF · 5d ago
Maxim Group Gives a Buy Rating to Plus Therapeutics (PSTV)
Maxim Group analyst Jason McCarthy assigned a Buy rating to Plus Therapeutics (PSTV) yesterday and set a price target of $6.00. The company's shares
SmarterAnalyst · 02/24 13:35
DJ Plus Therapeutics, Inc. CEO Marc Hedrick on Q4 2020 Results -- Earnings Call Transcript >PSTV
Dow Jones · 02/23 02:27
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PSTV. Analyze the recent business situations of Plus Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PSTV stock price target is 6.75 with a high estimate of 8.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 384.29K
% Owned: 4.19%
Shares Outstanding: 9.17M
TypeInstitutionsShares
Increased
5
119.66K
New
6
-65.97K
Decreased
5
14.87K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Director
Richard Hawkins
President
Steven Kesten
Chief Executive Officer/Director
Marc Hedrick
Chief Financial Officer/Vice President - Finance
Andrew Sims
Corporate Executive
Seijiro Shirahama
Senior Vice President
Gregory Stein
Chief Accounting Officer/Controller
Desiree Smith
Vice President - Business Development/General Counsel
Jeremy Hayden
Other
Mark Marino
Independent Director
Howard Clowes
Independent Director
Robert Lenk
Independent Director
Greg Petersen
Independent Director
Annigje van Es-Johansson
  • Dividends
  • Splits
  • Insider Activity
No Data
About PSTV
Plus Therapeutics, Inc., formerly Cytori Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma.

Webull offers kinds of Plus Therapeutics Inc stock information, including NASDAQ:PSTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTV stock methods without spending real money on the virtual paper trading platform.